CD19 and neuroblastoma: Indeed, autologous CAR-engineered VSTs have been evaluated in clinical trials targeting GD2 for neuroblastoma (45, 46), and allogeneic HCT donor-derived CAR+ VSTs targeting CD19 in B-acute lymphoblastic leukemia (47–49).